Happy 4th of July from all of us at MapLight Therapeutics, Inc.! As we celebrate Independence Day, we honor the courage and dedication of all those working towards a brighter future for our country and people with CNS conditions. Wishing everyone a safe and joyful holiday! 🇺🇸
MapLight Therapeutics, Inc.’s Post
More Relevant Posts
-
Discover the promising results from the phase III OAKS and DERBY trials of Pegcetacoplan, showing a significant slowing of GA lesion growth and an acceptable safety profile. Read more: https://lnkd.in/ewQr-_cg #eyenews #RetinaSpecialists #MedicalResearch
To view or add a comment, sign in
-
Did you catch our latest BioBreakthroughs yesterday? We won't even tell you it's a must listen, cause you know it is. Marcio Souza, CEO of Praxis Precision Medicines, Inc., shares insights on revolutionizing CNS drug development. Praxis is paving the way for groundbreaking CNS (central nervous system) treatments with their patient-centric and genetics-inspired approach. Thanks to Sage Growth Partners for being our partner in this episode. #CNSDrugDevelopment #BiotechInnovation #SoHCPodcasts
To view or add a comment, sign in
-
Positive Phase III trial results for a new ETRA
Novartis' $3.2B Chinook bet takes flight as phase 3 hits endpoint, providing launchpad for 2024 FDA filing
fiercebiotech.com
To view or add a comment, sign in
-
Class is back in session.
The kids are getting ready to go back to school. Remember to schedule time for yourself amid carpools, homework and after school activities. Check out our monthly newsletter and see what happening at Tranquil Healing Therapeutics. https://lnkd.in/gWfz4UmJ
To view or add a comment, sign in
-
-
Director, Market Access at Amgen (Rare Diseases) | Healthcare Committee Program Director at The American Chamber of Commerce Saudi Arabia
Unity makes strength, and strength is needed to serve patients! 💪🚀 #AmgenProud The five key takeaways: 1- Combined capabilities strengthen portfolio of innovative therapeutics that are first-in-class 2- Leverages Amgen's global footprint, world-class manufacturing, and experience with products early in their lifecycle 3- Reinforces Amgen's leadership expertise and long track record of developing and commercializing rare disease products in inflammation and nephrology 4- Enables a sustained investment in R&D innovation for long-term growth 5- Furthers our mission to serve patients living with serious illnesses, including rare diseases
With the October 2023 acquisition of Horizon Therapeutics, Amgen is now a leader in delivering innovative medicines to treat patients suffering from serious rare diseases. Here are 5️⃣ takeaways from today's business review. 🔗 Safe Harbor: https://amgen.ly/3uIspmA
To view or add a comment, sign in
-
Did you know that globally, bladder cancer is the 9th most commonly diagnosed cancer.* May is Bladder Cancer Awareness Month, a time to put a spotlight on a common but often overlooked cancer. Check out the Bladder Cancer Advocacy Network for information and resources. Go to DRUGDOCS® to find the clinical evidence for #PADCEV® (enfortumab vedotin-ejfv) used in the treatment of adult patients with urothelial cancer. #BladderCancerAwarenessMonth *Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. https://shr.link/p7l0r
DRUGDOCS® | PADCEV®
shr.link
To view or add a comment, sign in
-
The Breakthrough Therapy Designation, which will expedite the development and regulatory review of TAR-200 in this setting, is based on findings from the phase 2b SUNRISE-1 trial. https://lnkd.in/gNfsQyq2
FDA grants TAR-200 Breakthrough Therapy Designation for BCG-unresponsive NMIBC
urologytimes.com
To view or add a comment, sign in
-
We're headed to #SCDM next week, are you?! Come see us at booth #305 to discuss how SDC can help support your clinical trials! Lucas Warner Derek Luther #clinicaltrials #CRO #clinicaltrialtechnologysolutions
To view or add a comment, sign in
-
-
Exciting to share that my colleague, Dr. Amy McKee, has been named a 2023 PharmaVoice Honoree! Dr. McKee was recognized on the list of top 100 influential people in the life sciences industry for her commitment to developing the next generation of industry leaders and her leadership in creating breakthrough strategies for sponsors. Read our press release here: #CRO #healthcare #Oncology #patients #CMO #Parexel #withheart #Clinicalresearch #clinicaltrials
Parexel’s Amy McKee, M.D. Named to 2023 PharmaVoice 100 | Parexel International Corporation
share.parexel.social
To view or add a comment, sign in